for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Solid Biosciences Inc

SLDB.OQ

Latest Trade

4.66USD

Change

0.33(+7.62%)

Volume

221,068

Today's Range

4.34

 - 

4.73

52 Week Range

2.76

 - 

32.84

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.33
Open
4.42
Volume
221,068
3M AVG Volume
16.59
Today's High
4.73
Today's Low
4.34
52 Week High
32.84
52 Week Low
2.76
Shares Out (MIL)
46.00
Market Cap (MIL)
199.13
Forward P/E
-1.53
Dividend (Yield %)
--

Latest Developments

More

Solid Biosciences Files For Offering Of Up To 12.9 Mln Shares Of Common Stock Of Co By Selling Stockholders

Solid Biosciences Inc QTRLY Loss Per Share $0.76

Solid Biosciences Announces $60 Mln Private Placement With New And Existing Investors

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Solid Biosciences Inc

Solid Biosciences Inc., formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies platform is engaged in the development of gene therapy candidates for DMD. Its lead program, SGT-001, is an adeno-associated virus (AAV) microdystrophin gene therapy candidate, which focuses on enabling the systemic delivery of a shortened yet functional version of the dystrophin gene. The Company is examining small molecule and biologic candidates that may help manage the secondary disorders associated with DMD. It is developing Wearable support for patients with DMD. The hardware of its assistive devices is composed of three technologies: force generating actuators (or motors), electrically controlled clutches, and harness technology called Flex Grip.

Industry

Biotechnology & Drugs

Contact Info

141 Portland St Fl 5

+1.617.3374680

https://www.solidbio.com/

Executive Leadership

Andrey J. Zarur

Chairman of the Board, Co-Founder

Ilan Ganot

President, Chief Executive Officer, Co-Founder, Director

Jennifer Ziolkowski

Chief Financial Officer, Treasurer

Alvaro Amorrortu

Chief Operating Officer

Joel Schneider

Chief Technology Officer and Head of Exploratory Research and Development

Key Stats

2.75 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-2.880

2018

-2.250

2019(E)

-2.822
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.84
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.89
LT Debt To Equity (MRQ)
0.72
Return on Investment (TTM)
-82.41
Return on Equity (TTM)
-74.57

Latest News

Latest News

Solid Biosciences shares plummet as gene therapy trial halted again

Shares in Solid Biosciences Inc plunged 71% on Tuesday after a trial testing its gene therapy for a muscle-wasting disorder was halted for the second time in less than two years.

Solid Biosciences gene therapy trial put on hold by FDA

Solid Biosciences Inc said on Tuesday the U.S. Food and Drug Administration has put on hold a trial testing its gene therapy for a muscle-wasting disorder.

BRIEF-Boxer Capital Reports 6.2 Pct Passive Stake In Solid Biosciences

* BOXER CAPITAL, LLC REPORTS 6.2 PERCENT PASSIVE STAKE IN SOLID BIOSCIENCES INC AS OF MAY 9 - SEC FILING Source text: (https://bit.ly/2GwS8zg) Further company coverage:

BRIEF-Solid Biosciences Reports Quarterly Loss Per Share Of $0.54

* SOLID BIOSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular Dystrophy

* SOLID BIOSCIENCES PROVIDES UPDATE ON SGT-001 CLINICAL DEVELOPMENT PROGRAM FOR DUCHENNE MUSCULAR DYSTROPHY

BRIEF-Solid Biosciences Reports Full Year 2017 Financial Results And Provides Corporate Update

* SOLID BIOSCIENCES REPORTS FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Solid Biosciences Announces Clinical Hold On SGT-001 Phase I/Ii Clinical Trial

* SOLID BIOSCIENCES ANNOUNCES CLINICAL HOLD ON SGT-001 PHASE I/II CLINICAL TRIAL FOR DUCHENNE MUSCULAR DYSTROPHY

BRIEF-Solid Biosciences Says Now Sees IPO Of 7 Mln Shares Of Common Stock Priced Between $18-$19/Shr - SEC Filing

* SOLID BIOSCIENCES LLC SAYS NOW SEES IPO OF 7.0 MILLION SHARES OF COMMON STOCK PRICED BETWEEN $18.00 AND $19.00 PER SHARE - SEC FILING

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up